Table 7.
Immunohistochemical profile, classification, and tumor evolution classes.
| Clinical outcomes | p value∗ | |||
|---|---|---|---|---|
| Regrowth/recurrence (%) (n = 17) |
Stability (%) (n = 13) |
Reduction/cure (%) (n = 20) |
||
| Immunohistochemistry | ||||
| Hormone expression | 0.2193 | |||
| GH | 3 (18) | 2 (15) | 9 (45) | |
| PRL | 3 (18) | 1 (8) | 4 (20) | |
| ACTH | 2 (11) | 1 (8) | 0 (0) | |
| LH/FSH | 3 (18) | 1 (8) | 3 (15) | |
| Null cell | 6 (35) | 8 (61) | 4 (20) | |
| p53 | 0.0035 | |||
| <3+ | 3 (18) [−2] | 10 (77) [3] | 6 (33) [−1] | |
| ≥3+ | 14 (82) [2] | 3 (23) [−3] | 12 (67) [1] | |
| Ki-67 | 0.2329 | |||
| <2+ | 11 (65) | 11 (85) | 10 (56) | |
| ≥2+ | 6 (35) | 2 (15) | 8 (44) | |
| c-erbB2 | 0.7118 | |||
| <2+ | 4 (25) | 5 (38) | 6 (35) | |
| ≥2+ | 12 (75) | 8 (62) | 11 (65) | |
|
| ||||
| Classification | ||||
| Anatomical | 0.5155 | |||
| Noninvasive | 1 (6) | 2 (15) | 0 (0) | |
| Invasive | 16 (94) | 11 (85) | 20 (100) | |
| Pathological | 0.0145 | |||
| Nonproliferative | 4 (24) [−2] | 10 (77) [3] | 9 (45) [0] | |
| Proliferative | 13 (76) [2] | 3 (23) [−3] | 11 (55) [0] | |
| Clinicopathological | 0.0127 | |||
| Grades | ||||
| 1A | 0 (0) [−1] | 2 (15) [2] | 0 (0) [−1] | |
| 1B | 1 (6) [1] | 0 (0) [−1] | 0 (0) [−1] | |
| 2A | 4 (24) [−2] | 8 (62) [2] | 9 (45) [0] | |
| 2B | 12 (70) [2] | 3 (23) [−2] | 11 (55) [0] | |
∗Pearson's chi-square test; values expressed as frequency (%) and [Pearson residual] were tested to identify variables that contributed to statistical significance.